210 related articles for article (PubMed ID: 9415870)
1. The role of innovation in drug development.
Drews J; Ryser S
Nat Biotechnol; 1997 Dec; 15(13):1318-9. PubMed ID: 9415870
[No Abstract] [Full Text] [Related]
2. US NHGRI launches chemical attack on drug development gap.
Garber K
Nat Biotechnol; 2003 Nov; 21(11):1253-4. PubMed ID: 14595338
[No Abstract] [Full Text] [Related]
3. Implications of pharmacogenomics for drug development and clinical practice.
Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
[TBL] [Abstract][Full Text] [Related]
4. The state of innovation in drug development.
Kola I
Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
[TBL] [Abstract][Full Text] [Related]
5. Drug evaluation, drug development and pharmacogenetics: celebrating 30 years of progress.
Li Wan Po A
J Clin Pharm Ther; 2005 Feb; 30(1):1-4. PubMed ID: 15658998
[No Abstract] [Full Text] [Related]
6. [The future of pharmacogenetics--cost-effectiveness and barriers].
Gyrd-Hansen D
Ugeskr Laeger; 2005 May; 167(20):2153-5. PubMed ID: 15987071
[No Abstract] [Full Text] [Related]
7. Pharmaceutical research: cost savings through innovation.
Cohen KR; Levy RA
AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463
[No Abstract] [Full Text] [Related]
8. Will pharmacogenomics alter the role of patents in drug development?
Eisenberg RS
Pharmacogenomics; 2002 Sep; 3(5):571-4. PubMed ID: 12223043
[No Abstract] [Full Text] [Related]
9. Viewpoint: pharmaceutical innovation in Europe.
Baines E
Circulation; 2007 Jan; 115(2):f5-6. PubMed ID: 17228009
[No Abstract] [Full Text] [Related]
10. [Pharmacogenetic/regulatory aspects seen from the viewpoint of the industry].
Hansen L; Andersen D
Ugeskr Laeger; 2005 May; 167(20):2160-4. PubMed ID: 15987073
[No Abstract] [Full Text] [Related]
11. The power of genomics to transform the biotechnology industry.
Haseltine WA
Nat Biotechnol; 1998 May; 16 Suppl():25-7. PubMed ID: 9591259
[No Abstract] [Full Text] [Related]
12. Plotting the trajectories of tomorrow's magic bullets.
Nat Rev Drug Discov; 2004 Sep; 3(9):723. PubMed ID: 15368650
[No Abstract] [Full Text] [Related]
13. PK/PD modelling and simulations: utility in drug development.
Rajman I
Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
[TBL] [Abstract][Full Text] [Related]
14. New drugs from old--revisited.
Wyllie MG
BJU Int; 2009 Nov; 104(9):1301-2. PubMed ID: 19824965
[No Abstract] [Full Text] [Related]
15. The economics of drug development: a grim reality and a role for clinical pharmacology.
Honig P; Lalonde R
Clin Pharmacol Ther; 2010 Mar; 87(3):247-51. PubMed ID: 20160740
[No Abstract] [Full Text] [Related]
16. Recent advances in the pharmacogenetics of cancer chemotherapy.
Watters JW; McLeod HL
Curr Opin Mol Ther; 2002 Dec; 4(6):565-71. PubMed ID: 12596358
[TBL] [Abstract][Full Text] [Related]
17. Two decades of orphan product development.
Haffner ME; Whitley J; Moses M
Nat Rev Drug Discov; 2002 Oct; 1(10):821-5. PubMed ID: 12360259
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics in drug discovery and development: a translational perspective.
Roses AD
Nat Rev Drug Discov; 2008 Oct; 7(10):807-17. PubMed ID: 18806753
[TBL] [Abstract][Full Text] [Related]
19. Rediscovering plant-based drugs.
Littleton J; Falcone D; Davies HM
Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
[No Abstract] [Full Text] [Related]
20. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
Little S
IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
